SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Nieminen A.) "

Search: WFRF:(Nieminen A.)

  • Result 1-10 of 233
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Ruilope, LM, et al. (author)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • In: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Journal article (peer-reviewed)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
10.
  • Sliz, E., et al. (author)
  • Evidence of a causal effect of genetic tendency to gain muscle mass on uterine leiomyomata
  • 2023
  • In: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 14:1
  • Journal article (peer-reviewed)abstract
    • Uterine leiomyomata (UL) are the most common tumours of the female genital tract and the primary cause of surgical removal of the uterus. Genetic factors contribute to UL susceptibility. To add understanding to the heritable genetic risk factors, we conduct a genome-wide association study (GWAS) of UL in up to 426,558 European women from FinnGen and a previous UL meta-GWAS. In addition to the 50 known UL loci, we identify 22 loci that have not been associated with UL in prior studies. UL-associated loci harbour genes enriched for development, growth, and cellular senescence. Of particular interest are the smooth muscle cell differentiation and proliferation-regulating genes functioning on the myocardin-cyclin dependent kinase inhibitor 1A pathway. Our results further suggest that genetic predisposition to increased fat-free mass may be causally related to higher UL risk, underscoring the involvement of altered muscle tissue biology in UL pathophysiology. Overall, our findings add to the understanding of the genetic pathways underlying UL, which may aid in developing novel therapeutics.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 233
Type of publication
journal article (218)
conference paper (9)
research review (5)
book chapter (1)
Type of content
peer-reviewed (224)
other academic/artistic (9)
Author/Editor
Nieminen, P (45)
Julin, R. (26)
Juutinen, S. (26)
Rahkila, P. (25)
Uusitalo, J. (25)
Leino, M. (25)
show more...
Nieminen, T. (22)
Nieminen, M. S. (21)
Scholey, C. (20)
Greenlees, P. T. (20)
Nieminen, M (20)
Grahn, T. (18)
Wedel, H. (18)
Pakarinen, J. (17)
Dahlöf, Björn, 1953 (16)
Cederwall, Bo (15)
Kettunen, H. (14)
Sinisalo, J. (12)
Sarén, J. (12)
Ingelsson, Erik (12)
Jones, P (12)
Lindholm, Lars H (12)
Collins, R (11)
Groop, Leif (11)
Salomaa, Veikko (11)
Perola, Markus (11)
Sandzelius, M. (11)
Petaja, T. (11)
de Faire, U (11)
Wyss, Ramon (11)
de Faire, Ulf (11)
Page, R. D. (11)
Caulfield, M (11)
Ostergren, J. (11)
Nyman, M (11)
Boerwinkle, Eric (11)
Sorri, J. (11)
Devereux, R. B. (11)
Kulmala, M (10)
Makitie, A (10)
Mahajan, A. (10)
Jukema, JW (10)
O'Brien, E (10)
Fazekas, F. (10)
Morais, J (10)
Ruotsalainen, P. (10)
Johansson, Åsa (10)
Samani, Nilesh J. (10)
Gyllensten, Ulf (10)
Peura, P. (10)
show less...
University
Karolinska Institutet (97)
University of Gothenburg (51)
Uppsala University (44)
Lund University (36)
Royal Institute of Technology (28)
Umeå University (27)
show more...
Stockholm University (14)
Chalmers University of Technology (9)
Linköping University (5)
Luleå University of Technology (4)
RISE (2)
Swedish University of Agricultural Sciences (2)
Örebro University (1)
Stockholm School of Economics (1)
Mid Sweden University (1)
show less...
Language
English (232)
Spanish (1)
Research subject (UKÄ/SCB)
Natural sciences (70)
Medical and Health Sciences (64)
Engineering and Technology (3)
Social Sciences (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view